<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26765">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01941615</url>
  </required_header>
  <id_info>
    <org_study_id>1241.31</org_study_id>
    <secondary_id>2013-000298-62</secondary_id>
    <nct_id>NCT01941615</nct_id>
  </id_info>
  <brief_title>Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel</brief_title>
  <official_title>An Open-label, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of BI 207127 + Faldaprevir on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the effect of multiple oral doses of BI 207127 + faldaprevir (FDV) on the
      multiple dose pharmacokinetics of ethinylestradiol and levonorgestrel (Microgynon速) in
      healthy premenopausal female volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUCt,ss (area under the concentration-time curve of ethinylestradiol in plasma at steady state over a uniform dosing interval t)</measure>
    <time_frame>up to 24 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss (maximum measured concentration of ethinylestradiol in plasma at steady state over a uniform dosing interval t)</measure>
    <time_frame>up to 24 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>C24,ss (measured concentration of ethinylestradiol in plasma at steady state 24 hours after drug administration)</measure>
    <time_frame>up to 24 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt,ss (area under the concentration-time curve of levonogestrel in plasma at steady state over a uniform dosing interval t)</measure>
    <time_frame>up to 24 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss (maximum measured concentration of levonogestrel in plasma at steady state over a uniform dosing interval t)</measure>
    <time_frame>up to 24 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>C24,ss (measured concentration of levonogestrel in plasma at steady state 24 hours after drug administration)</measure>
    <time_frame>up to 24 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 207127 + faldaprevir + Microgynon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period A: Microgynon速;  Period B: Microgynon速  + FDV + BI 207127</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>faldaprevir</intervention_name>
    <description>oral doses for 10 days (period B)</description>
    <arm_group_label>BI 207127 + faldaprevir + Microgynon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microgynon速</intervention_name>
    <description>oral doses for 23 days (period A+B)</description>
    <arm_group_label>BI 207127 + faldaprevir + Microgynon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>oral doses for 10 days (period B)</description>
    <arm_group_label>BI 207127 + faldaprevir + Microgynon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy female subjects

          -  Age 18 to 35 years (inclusive)

          -  Body Mass Index 20-29.9 kg/m2

          -  Use of hormonal contraception (i.e. oral contraceptives, hormonal contraceptive
             vaginal ring, but not hormone-containing intrauterine devices, depot injections or
             contraceptive implants)

        Exclusion criteria:

          -  Any relevant deviation from healthy conditions

          -  Subject is assessed by the investigator as unsuitable for inclusion, for instance,
             because considered not able to understand and comply with study requirements, or has
             a condition that would not allow safe participation in the study

          -  Positive pregnancy test, pregnancy or planning to become pregnant within 1 month of
             study completion, or lactation

          -  Any relevant finding of the gynaecological examination

          -  Thrombotic predisposition according to thrombophilic testing

          -  Existing or history of arterial thrombotic or embolic processes, conditions which
             predispose to them e.g. disorders of the clotting processes, valvular heart disease
             and atrial fibrillation

          -  Existing or history of confirmed venous thromboembolism, family history of venous
             thromboembolism, and other known risk factors for venous thromboembolism.

          -  Relevant varicosis

          -  No use of an additional contraceptive method from screening examination until 1 month
             after last study drug administration (acceptable methods are considered to be barrier
             methods, sexual abstinence, non-hormone-containing intrauterine device, or
             vasectomisation for the male partner).

        Use of hormone-containing intrauterine device, depot injection or contraceptive implants

          -  Any history of relevant liver diseases (e.g. disturbances of liver function, jaundice
             or persistent itching during a previous pregnancy, Dubin-Johnson syndrome, Rotor
             syndrome, or previous or existing liver tumours)

          -  AST (aspartate transaminase) and/or ALT (alanine transaminase) &gt; 1.5 ULN (upper limit
             of normal)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1241.31.2 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 5, 2014</lastchanged_date>
  <firstreceived_date>September 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
